Zepbound®
US$ 29.44
glp 1 clinical trials Another milestone in the evolution of GLP-1-based diabetes therapies You might know them as
Description
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology
Eli Lilly has seven additional Phase 3 TRIUMPH trials expected to complete during the course of the coming months and into the following year
2 The administration of GLP-1 agonists (GLP-1As) can sufficiently replace the action of incretins and lower glucose levels
The effects of semaglutide on kidney oxygenation, albuminuria and eGFR will be assessed in people with type 1 diabetes as part of the REMODEL-T1D mechanistic trial (NCT05822609)
